Autopsy report · NCT03932513

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study was halted due to suspected liver injury in another study with Inarigavir”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 8 months before it stopped.
8 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: F-star Therapeutics, Inc.
Sponsor type: Industry
Conditions: HBV; Hepatitis B; Hepatitis B, Chronic
Interventions: inarigivir soproxil
Participants: 8
Sites: 1
Countries: Singapore

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.